Etrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos. 2008 Oct; 36(ten):2064?9. [PubMed: 18653742] 34. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib around the progression of coronary atherosclerosis. N Engl J Med. 2007 Mar 29; 356(13):1304?six. [PubMed: 17387129] 35. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007 Apr 19; 356(16):1620?0. [PubMed: 17387131] 36. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007 Jul 14; 370(9582):153?0. [PubMed: 17630038] 37. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in sufferers at higher danger for coronary events. N Engl J Med. 2007 Nov 22; 357(21):2109?two. [PubMed: 17984165] 38. Rader DJ. Illuminating HDL–is it nevertheless a viable therapeutic target? N Engl J Med. 2007 Nov 22; 357(21):2180?. [PubMed: 17984168] 39. Hewing B, Fisher EA. Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol. 2012 Apr 18. 40. Bentley D, Young AM, Rowell L, et al. Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat. J Cardiovasc Pharmacol. 2012 Jul 19. 41. Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):32E?E. 42. Derks M, Anzures-Cabrera J, Turnbull L, et al. Safety, tolerability and pharmacokinetics of dalcetrapib following single and a number of ascending doses in healthier subjects: a randomized, double-blind, placebo-controlled, phase I study. Clin Drug Investig. 2011; 31(five):325?5. 43. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains effective pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010 Dec; 51(12):3443?four. [PubMed: 20861162] 44. Kuhlmann O, Heinig K. Dalcetrapib pharmacokinetics and metabolism inside the cynomolgus monkey.Bathocuproine Formula Xenobiotica.1071520-51-8 In stock 2011 May; 41(5):430?.PMID:22943596 [PubMed: 21348578] 45. Derks M, Kawamura H, Abt M, et al. Effects of meals intake around the pharmacokinetic properties of dalcetrapib: findings from 3 phase I, single-dose crossover studies in healthful volunteers. Clin Ther. 2011 Jun; 33(six):754?five. [PubMed: 21704240] 46. Xiao D, Shi D, Yang D, et al. Carboxylesterase-2 can be a hugely sensitive target in the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs. Biochem Pharmacol. 2013 Feb 1; 85(3):439?7. [PubMed: 23228697]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptClin Pharmacokinet. Author manuscript; accessible in PMC 2014 August 01.Mohammadpour and AkhlaghiPage47. Derks M, Abt M, Phelan M, et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol. 2010 Oct; 50(ten): 1188?01. [PubMed: 20489031] 48. Derks M, Abt M, Parr G, et al. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Professional Opin Investig Drugs. 2010 Oct; 19(10):1135?5. 49. Derks M, Abt M, Phelan M. Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.